Critical Contrast: VanEck Biotech ETF (NASDAQ:BBH) and Nuveen Sl Tfip (NYSE:NXP)

Nuveen Sl Tfip (NYSE:NXP) and VanEck Biotech ETF (NASDAQ:BBH) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Institutional & Insider Ownership

16.2% of Nuveen Sl Tfip shares are owned by institutional investors. Comparatively, 32.0% of VanEck Biotech ETF shares are owned by institutional investors. 1.0% of Nuveen Sl Tfip shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Nuveen Sl Tfip and VanEck Biotech ETF, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuveen Sl Tfip	0	0	0	0	0.00
VanEck Biotech ETF	0	6	1	0	2.71

VanEck Biotech ETF has a consensus target price of $190.23, indicating a potential upside of 0.00%. Given VanEck Biotech ETF’s stronger consensus rating and higher probable upside, analysts clearly believe VanEck Biotech ETF is more favorable than Nuveen Sl Tfip.

Dividends

Nuveen Sl Tfip pays an annual dividend of $0.43 per share and has a dividend yield of 3.0%. VanEck Biotech ETF pays an annual dividend of $1.25 per share and has a dividend yield of 0.7%.

Risk and Volatility

Nuveen Sl Tfip has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, VanEck Biotech ETF has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Valuation & Earnings

This table compares Nuveen Sl Tfip and VanEck Biotech ETF”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuveen Sl Tfip	$29.54 million	29.96	N/A	N/A	N/A
VanEck Biotech ETF	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Nuveen Sl Tfip and VanEck Biotech ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuveen Sl Tfip	N/A	N/A	N/A
VanEck Biotech ETF	N/A	N/A	N/A

Summary

VanEck Biotech ETF beats Nuveen Sl Tfip on 5 of the 8 factors compared between the two stocks.

About Nuveen Sl Tfip

Nuveen Select Tax-Free Income Portfolio is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of United States. The fund invests in the investment-grade municipal securities rated Baa and BBB or better. It benchmarks the performance of its portfolio against the Standard & Poor's (S&P) National Municipal Bond Index and Lipper General and Insured Unleveraged Municipal Debt Funds Average. Nuveen Select Tax-Free Income Portfolio was formed on March 19, 1992 and is domiciled in the United States.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.